Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 35-50 , February 2001

Mitomycin C: a clinical update

References 

    REFERENCES
  1. Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev. 1976;3:121–139
  2. Physicians’ Desk Reference, Oradell, NJ, Medical Economics Company, 1975, 642, 643.
  3. Physicians’ Desk Reference. 2000;
  4. Doll DC, Weiss RB, Issell BF. Mitomycin: 10 years after approval for marketing. J Clin Oncol. 1985;3:276–286
  5. DeVita, V. T. Hellman, S. Rosenberg, S. A. Cancer: Principles and Practice of Oncology, Philadelphia, J.B. Lippincott, 1997
  6. O’shaughnessy JA, Wittes RE, Burke G. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol. 1991;9:2225–2232
  7. Smith PH. Chemotherapy of bladder cancer: a review. Cancer Treat Rep. 1981;65:165–173
  8. Tannock IF. Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract. Cancer Treat Rep. 1983;67:503–504
  9. James ND, Hussain S, Moffitt D, Glaholm J, Peake D. A phase I/II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer [abs 1404]. Proc Am Soc Clin Oncol. 2000;19:356a
  10. Bracken RB, Johnson DE, von Eschenbach AC, Swanson DA, De Furia D, Crooke S. Role of intravesical mitomycin C in management of superficial bladder tumors. Urology. 1980;16:11–13
  11. Huland H, Otto U. Use of mitomycin as prophylaxis following endoscopic resection of superficial bladder cancer. Urology. 1985;26:32–35
  12. Devonec M, Bouvier R, Sarkissian J, Bendimerad O, Gelet A, Dubernard JM. Intravesical instillation of mitomycin C in the prophylactic treatment of recurring superficial transitional cell carcinoma of the bladder. Brit J Urol. 1983;55:382–385
  13. Harrison GSM, Green DF, Newling WW, Richards B, Robinson MRG, Smith PH. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer. Brit J Urol. 1983;55:676–679
  14. Boccardo F, Cannata D, Rubagotti A. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. J Clin Oncol. 1994;12:7–13
  15. Kondas J, Kiss L, Hatar A. The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. Int Urol Nephrol. 1999;31:451–456
  16. Huland H, Otto U. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Eur Urol. 1983;9:84–86
  17. Koontz WW, Heney NM, Soloway MS. Mitomycin for patients who have failed thiotepa. Urology. 1985;26:30–31
  18. Stricker PD, Grant ABF, Hoskin BM, Taylor JS. Topical mitomycin C therapy for carcinoma in situ of the bladder: a follow-up. J Urol. 1990;143:34–36
  19. Sekine H, Fukui I, Yamada T, Ohwada F, Yokokawa M, Ohshima H. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer follow-up result. J Urol. 1994;151:27–30
  20. van Gils-Gielen RJM, Debruyne FMJ, Witjes WPJ, Witjes JA, Caris CTM, Oosterhof GON. Risk factors in carcinoma in situ of the urinary bladder. Urology. 1995;45:581–586
  21. De Bruijn EA, Sleeboom HP, van Helsdingen PJRO, van Oosterom AT, Tjaden UR, Maes RAA. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int J Urol. 1992;51:359–364
  22. Jauhiainen K, Sotarauta M, Permi J, Alfthan O. Effect of mitomycin-C and doxorubicin on carcinoma in situ of the urinary bladder. Eur Urol. 1986;12:32–37
  23. Alfthan O, Jauhiainen K. Instillation of superficial bladder cancer with mitomycin C and doxorubicin [abstract 684]. J Urol. 1986;135:275A
  24. Liberti M, De Berardinis E, Tenaglia R, Verri A, Tacciuoli M. Intravesical therapy with adriamycin and mitomycin C in 102 patients who underwent T.U.R. or T.V.R. for superficial bladder tumors Pt1G1-G3[abstract 50]. Prostate. 1983;B668–699
  25. Mori K, Lamm DL, Crawford ED. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a south-west Oncology Group study. Urol Int. 1986;41:254–259
  26. Malmström P-U, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1999;161:1124–1127
  27. Witjes JA, vd Meijden APM, Collette L. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. Urology. 1998;52:410–493
  28. Wientjes MG, Knemeyer IW, Kalns J, Warner J, Au JL-S. Pharmacokinetic interventions during intravesical mitomycin C therapy; interim report on results of a multicenter phase III trial [abstract 1581]. Proc Am Assoc Cancer Res. 1999;40:238
  29. Au JL-S, Wientjes MG, Badalament RA. Pharmacokinetic interventions improve the efficacy of intravesical mitomycin C therapy of superficial bladder cancer patients: results of a phase III trial. Am Assoc Cancer Res Annual Mtg. 1999;
  30. Baker C, Allen HJ, Bosserman LD, Figlin RA. A phase II evaluation of gemcitabine plus docetaxel as therapy for advanced transitional cell carcinoma of the urothelial tract [abstract 1437]. Proc Am Soc Clin Oncol. 2000;19:364a
  31. Meluch AA, Greco FA, Burris HA. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma (TCC) of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research network [abstract 1338]. Proc Am Soc Clin Oncol. 2000;19:340a
  32. Hortobagyi GN. Mitomycin-C in breast cancer. Sem Oncol. 1985;12:65–70
  33. Legha SS. A review of mitomycin regimens in advanced breast cancer therapy. Clin Therapeut. 1985;7:286–307
  34. Lenaz L. Mitomycin C in advanced breast cancer. Cancer Treat Rev. 1985;12:235–249
  35. Garewal HS. Mitomycin C in chemotherapy of advanced breast cancer. Sem Oncol. 1988;15:74–79
  36. Godfrey TE. Mitomycin C in advanced breast cancer: an update. Sem Oncol. 1988;15:71–73
  37. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two doses schedules of mitomycin C in advanced breast cancer. Cancer. 1992;69:476–481
  38. Dieras V, Marty M. Tubiana N et al. Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer. Sem Oncol. 1995;22:33–39
  39. Brambilla C, Zambetti M, Ferrari L, Bonadonna G. Mitomycin C and vinblastine in advanced refractory breast cancer. Tumori. 1989;75:141–144
  40. Navarro M, Bellmunt J, Balana C, Colomer R, Jolis L, del Campo LJ. Mitomycin-C and vinblastine in advanced breast cancer. Oncology. 1989;46:137–142
  41. Perrone F, De Placido S, Carlomagno C. Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. Tumori. 1993;79:254–257
  42. Nabholtz JM, Senn HJ, Bezwoda WR. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatice breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17:1413–1424
  43. Lyss A, Luedke S, Einhorn L, Luedke DW, Ramey M. Vindesine and mitomycin C in metastatic breast cancer. Oncology. 1989;46:357–359
  44. Rausa L, Russo A, Gebbia V, Gebbia N, D’Alessandro N, Palmeri S. Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. J Cancer Res Clin Oncol. 1991;117:266–268
  45. Degardin M, Hecquet B, Bonneterre J, Adenis A, Pion JM, Demaille A. A study of VMMC protocol (vindesine, mitoxantrone, mitomycin C) as a salvage chemotherapy in advanced breast cancers. Bull Cancer. 1992;79:169–176
  46. Degardin M, Bonneterre J, Hecquet B. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol. 1994;5:423–426
  47. Toussaint C, Izzo J, Spielmann M. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol. 1994;12:2102–2112
  48. Twelves CJ, Dobbs NA, Curnow A. A Phase II, multicentre, U.K. study of vinorelbine in advanced breast cancer. Br J Cancer. 1994;70:990–993
  49. Barni S, Ardizzoia A, Bernardo G. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori. 1994;80:282–290
  50. Gasparini G, Caffo O, Barni S. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer paients: a phase II study. J Clin Oncol. 1994;;12:2094–2101
  51. Terenziani M, Demicheli R, Brambilla C. Vinorelbine: an active, non-cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat. 1996;39:285–291
  52. Gasco M, Gardin G, Repetto L, Campora E, Rosso R. Vinorelbine as palliative therapy in advanced breast cancer. Anticancer Res. 1997;17:1431–1433
  53. Scheithauer W, Kornek G, Haider K. Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res Treat. 1993;26:49–55
  54. Agostara B, Gebbia V, Testa A, Cusimano MP, Gebbia N, Callari AM. Mitomycin ‘C’ and vinorelbine as second line chemotherapy for metastatic breast cancer. Tumori. 1994;80:33–36
  55. Vici P, DiLauro L, Carpano S. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. Oncology. 1996;53:16–18
  56. Kornek GV, Haider K, Kwasny W. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer. 1996;74:1668–1673
  57. Colleoni M, Manente P, Stocker J. Mitomycin C and vinorelbine in pretreated breast cancer. Tumori. 1997;83:834–836
  58. Colleoni M, Manente P, Stocker J. A randomized phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer. Oncology. 1997;54:438–439
  59. De Placido S, Lauria R, Perrone F. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study. Oncology. 2000;58:8–14
  60. Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer with minimal gastrointestinal toxcity and alopecia. Cancer Chemother Pharmacol. 1990;26:457–460
  61. Powles TJ, Jones AL, Judson IR, Hardy JR Ashley SE. A randomized trial comparing combination chemotherapy using mitomycin C, mitoxantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer. Br J Cancer. 1991;64:406–410
  62. Stein RC, Bower M, Law M. Mitoxantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomized clinical trial. Eur J Cancer. 1992;28A:1963–1965
  63. Astone A, Cassano A, Fontana T, Noviello MR, Pozzo C, Barone C. Salvage chemotherapy with mitoxantrone and mitomycin with and without methotrexate in advanced breast cancer. Anticancer Drugs. 1992;3:471–473
  64. Perrone F, DePlacido S, Carlomagno C. Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. Am J Clin Oncol. 1994;17:218–222
  65. Muhonen T, Jantunen I, Pertovaara H. Prophylactic filgrastim (G-CFS) during mitomycin C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer: a randomized study. Am J Clin Oncol. 1996;19:232–234
  66. Sekine I, Sasaki Y, Fujii H. Recurrent breast cancer treated successfully with mitomycin C and vinblastine after failure of both doxorubicin-containing regimen and paclitaxel – a case report. Tohoku J Exp Med. 1996;178:331–337
  67. Davidson NPG, Davis AS, Woods J, Snooks S, Cheverton PD. FILM (5-fluorouracil, ifosfamide, leucovorin and mitomycin C), an alternative chemotherapy regimen suitable for the treatment of advanced breast cancer in the ‘out-patient’ setting. Cancer Chemother Pharmacol. 1999;44:S18–S23
  68. Yoshimoto M, Saito M, Takashi T. Results of a randomized phase III trial comparing high dose mitomycin C (MMC) administered immediately after surgery followed by CMF and CMF alone in node-positive, premenopausal breast cancer (BC) patients (Pts). Proc Am Soc Clin Oncol. 2000;19 (95a abs 364):
  69. Sivanesaratnam V, Jayalakshmi P, Mitomycin C. adjuvant chemotherapy after Wertheim’s hysterectomy for stage 1B cervical cancer. Cancer. 1989;64:798–800
  70. Thigpen T, Blessing JA, Gallup DG, Maiman M, Soper JT. Phase II trial of mitomycin C in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1995;57:376–379
  71. Miyamoto T, Takabe Y, Watanabe M, Terasima T. Effectiveness of a sequential combination of bleomycin and mitomycin-C on an advanced cervical cancer. Cancer. 1978;41:403–414
  72. Leichman LP, Baker LH, Stanhope CR. Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a south-west Oncology Group pilot study. Cancer Treat Rep. 1980;64:1139–1140
  73. Krebs H-B, Girtanner RE, Nordqvist SRB, Mineau I, Averette HE. Treatment of advanced cervical cancer by combination of bleomycin and mitomycin-C. Cancer. 1980;46:2159–2161
  74. Greenberg BR, Hannigan J, Gerretson L. Sequential combination of bleomycin and mitomycin in advanced cervical cancer—an American experience: a northern California Oncology Group Study. Cancer Treat Rep. 1982;66:163–165
  75. Boice CR, Freedman RS, Herson J, Wharton JT, Rutledge FN. Bleomycin and mitomycin-C (BLM-M) in recurrent squamous uterine cervical carcinoma. Cancer. 1982;49:2242–2245
  76. Tropè C, Johnssom J-E, Simonsen E. Bleomycin- mitomycin in advanced carcinoma of the cervix. Cancer. 1983;51:591–593
  77. Copas P, Dyer M, Smithson LG, Hall DJ. Bleomycin- mitomycin in advanced squamous cell carcinoma of the female genital tract. Obstet Gynecol. 1983;61:308
  78. Baker LH, Opipari MI, Wilson H, Bottomly R, Coltman CA, Mitomycin C. vincristine and bleomycin therapy for advanced cervical cancer. Obstet Gyneco. 1978;52:146–150
  79. Swenerton KD, Evers JA, White GW, Boyes DA. Intermittent pelvic infusion with vincristine, bleomycin, and mitomycin C for advanced recurrent carcinoma of the cervix. Cancer Treat Rep. 1979;63:1379–1381
  80. Wheelock JB, Krebs HB, Goplerud DR. Bleomycin, vincristine, and mitomycin C (BOM) as second-line treatment after failure of cis-platinum-based combination chemotherapy for recurrent cervical cancer. Gynecol Oncol. 1990;37:21–23
  81. Malviya VK, Deppe G, Schoenmaker M. Treatment of recurrent cervical cancer with cis-platinum and mitomycin C: a phase II study. Am J Clin Oncol. 1989;12:438–441
  82. Senapad S, Neumgton S, Usavajindawath C, Vijatrasil S, Thaithanaisawanya V. Cis-platinum and mitomycin-C in treatment of recurrent, metastatic, or residual cervical cancer post radiation. J Med Assoc Thai. 1989;72:382–386
  83. Deppe G, Christensen CW. A preliminary report of combination chemotherapy with cisplatin and mitomycin C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol Oncol. 1991;42:178–181
  84. Ikeda K, Ogawa M, Inagaki J. et al. A combination chemotherapy using mitomycin C, vincristine and cisplatin (MVP) for advanced cervical cancer. Gan To Kagaku Ryoho. 1985;12:536–540
  85. Delaloye JF, Leyvraz S, Outcha-Adjahoto E, Bauer J, De-Grandi P. Salvage chemotherapy with mitomycin, vindesine, and cisplatin (MiViP) in recurrent carcinoma of the cervix. Am J Clin Oncol. 1996;;19:204–206
  86. Itoh N, Sawairi M, Hanabayashi T, Mori H, Yamawaki Y, Tamaya T. Neoadjuvant intraaterial infusion chemotherapy with a combination of mitomycin C, vincristine, and cisplatin for locally advanced cervical cancer: a preliminary report. Gynecol Oncol. 1992;47:391–394
  87. Park S-Y, Kim B-G, Kim J-H. Phase I/II study of neoadjuvant chemotherapy with mitomycin C, vincristine, and cisplatin in patients with stage IIb bulk cervical carcinoma. Cancer. 1995;76:814–823
  88. Vogl SE, Moukhtar M, Calanog A, Greenwald EH, Kaplan BH. Chemotherapy for advanced cervical cancer with bleomycin, vincristine, mitomycin C, and cisdiamminedichloroplatinum (II) (BOMP). Cancer Treat Rep. 1980;64:1005–1007
  89. Surwit EA, Alberts DS, Aristizabal S, Deatherge KJ, Heusinkveld R. Treatment of primary and advanced squamous cell cancer of the cervix with mitomycin C + vincristine + bleomycin (MOB) plus cisplatin (PLAT) [abstract C-596]. Proc Am Soc Clin Oncol. 1983;2:153
  90. Giannone L, Brenner DE, Jones HWIII, Greco FA, Burnett LS. Combination chemotherapy for patients with advanced carcinoma of the cervix: trial of mitomycin C, vincristine, bleomycin, and cisplatin. Gynecol Oncol. 1987;26:178–182
  91. Sugimori H, Iwasaka T, Fukuda K, Hayashi Y, Hachisuga T. Treatment of advanced cervical cancer by a combination of peplomycin, vincristine, mitomycin C, and cisplatin. Gynecol Oncol. 1989;34:180–182
  92. Shimizu Y, Akiyama F, Umezawa S, Ishiya T, Utsugi K, Hasumi K. Combination of conservative low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma. J Clin Oncol. 1998;16:1869–1878
  93. Dottino PR, Plaxe SC, Beddoe AM, Johnston C, Cohen CJ. Induction chemotherapy followed by radical surgery in cervical cancer. Gynecol Oncol. 1991;40:7–11
  94. Lipsztein R, Kredentser D, Dottino P. Combined chemotherapy and radiation therapy for advanced carcinoma of the cervix. Am J Clin Oncol. 1987;10:527–530
  95. Weiner SA, Aristizabal S, Alberts DS, Surwit EA, Deatherage-Deuser K. A phase II of mitomycin, vincristine, bleomycin, and cisplatin (MOBP) as neo-adjuvant therapy in high-risk cervical carcinoma. Gynecol Oncol. 1988;30:1–6
  96. Souhami L, Gil RA, Allan SE. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol. 1991;9:970–977
  97. Buroker TR, Kim PN, Baker LH, Ratanatharathorn V, Wojtaszak B, Vaitkevicius VK. Mitomycin C alone and in combination with infused 5-fluorouracil in the treatment of disseminated gastrointestinal carcinomas. Med Pediatric Oncol. 1978;4:35–42
  98. Poplin EA, LoRusso P, Lokich JJ. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1994;33:415–419
  99. Hartman JT, Harstrick A, Daikeler T. Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. Anticancer Drugs. 1998;9:427–431
  100. Anderson N, Lokich J, Moore C, Bern M, Coco F. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. Cancer Invest. 1999;17:586–593
  101. Floridi A, Paggi MG, D’Atri S. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 1981;41:4661–4666
  102. Zaniboni A, Meriggi F, Alghisi A. Mitomycin-C and Ionidamine as second-line therapy for colorectal cancer: a phase II study. Tumori. 1995;81:435–437
  103. Maiello E, Giotta F, Gebbia V. Mitomycin-C and Ionidamine as second-line treatment of advanced colorectal cancer patients. Anticancer Res. 1996;16:3177–3179
  104. Buroker TR, Kim PN, Groppe C. 5FU infusion with mitomycin C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer. Cancer. 1978;42:1228–1233
  105. Krauss S, Sonoda T, Solomon A. Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C. Cancer. 1979;43:1598–1603
  106. Vaughn CB, Brady P, Chinn BJ, Daversa GC, Parzuchowski JS. Combination chemotherapy in advanced gastrointestinal malignancy. Oncology. 1980;37:57–61
  107. Conti JA, Kemeny NE, Saltz LB, Andre AM, Grossano DD, Bertino JR. Continuous infusion fluorouracil/leucovorin and bolus mitomycin C as a salvage regimen for patients with advanced colorectal cancer. Cancer. 1995;75:769–774
  108. Ross P, Norman A, Cunningham D. A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Annals Oncol. 1997;8:995–1001
  109. Sietz JF, Perrier H, Giovannini M, Capodano G, Bernardini D, Bardou VJ. 5-fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother. 1998;10:258–265
  110. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. Annals Oncol. 2000;11:235–237
  111. Lancet. 1996;348:1049–1054
  112. Flam M, John M, Pajak TF. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–2539
  113. Bedikian AY. Regional and systemic chemotherapy for advanced colorectal cancer A review. Dis Colon Rectum. 1983;26:327–332
  114. Patt YZ, McBride CM, Ames FC. Adjuvant perioperative hepatic arterial mitomycin C and floxuridine combined with surgical resection of metastatic colorectal cancer in the liver. Cancer. 1987;59:867–873
  115. Wils J, Schlangen J, Naus A. Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma. Cancer Chemother Pharmacol. 1984;13:215–217
  116. Theodors A, Bukowski RM, Lavery I. Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study. Med Pediatric Oncol. 1982;10:463–470
  117. Schneider A, Kemeny N, Chapman D, Niedzwiecki D, Oderman P. Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. Cancer. 1989;64:2203–2206
  118. Makela J, Kantola R, Tikkakoski T. Superselective intra-arterial chemotherapy with mitomycin C in hepatic metastases from colorectal cancer. J Surg Oncol. 1997;65:127–131
  119. Tseng MH, Park HC. Pelvic intra-arterial mitomycin C infusion in previously treated patients with metastatic, unresectable, pelvic colorectal cancer and angiographic determination of tumour vascularity. J Clin Oncol. 1985;3:1093–1100
  120. Patt YZ, Peters RE, Chuang VP, Wallace S, Claghorn L, Mavligit G. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. Cancer. 1985;56:2175–2180
  121. Weber W, Laffer U, Metzger U. Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. SAKK. Anticancer Res. 1993;13:1839–1840
  122. Kouroussis Ch, Mavroudis D, Giannakakis Th. Biweekly oxaliplatin (L-OHP) with high-dose leucovorin (LV) and 5-fluorouracil (5-FU) 48-hour continuous infusion in pretreated patients with advanced colorectal cancer (CRC) [abstract IIII]. Proc Am Soc Clin Oncol. 1999;18:290a
  123. Preusser P, Achterrath W, Wilke H. Chemotherapy of gastric cancer. Cancer Treat Rev. 1988;15:257–277
  124. MacDonald JS, Schein PS, Woolley PV. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med. 1980;93:533–536
  125. Park JO, Chung HC, Cho JY. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin C (modified FAM) combination chemotherapy versus palliative therapy in the treatment of advanced gastric cancer. Am J Clin Oncol. 1997;20:484–489
  126. Raschko JW, Johnson EA, Ueno W, Woolley PV, Treat J. Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastic gastric carcinoma: an evaluation of efficacy and toxicity. Cancer Invest. 1991;9:49–51
  127. DeLisi V, Coccone G, Angelini F. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research. Cancer. 1996;77:245–250
  128. Koizumi W, Tanabe S, Kurihara M, Kondou I, Yamazaki I, Saigenji K. Pilot study of combined treatment with continuous infusion of 5-fluorouracil, mitomycin C, and cisplatin (FMP) in patients with inoperable advanced gastric cancer. Oncol Rep. 1999;6:643–646
  129. Tsavaris NB, Tentas K, Kosmidis P. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-Fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. Am J Clin Oncol. 1996;19:517–521
  130. Roth A, Zupano D, Luetic J, Kolaric K. Open phase II with 5-fluorouracil, 4-epidoxorubicin and mitomycin C (FEM) in advanced gastric cancer. Tumori. 1990;76:51–53
  131. Cascinu S, Latini L, Fedeli A. The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. Anticancer Res. 1995;15:2781–3783
  132. Yamao T, Kazami A, Handa T. Phase I/II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer [abstract 1174]. Proc Am Soc Clin Oncol. 1999;18:306a
  133. Shimada Y, Shirao K, Ohtsu A. Phase III study of JFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer: JCOG Study 9205. Proc Am Soc Clin Oncol. 1999;18:272a
  134. Hartmann JT, Quietzsch D, Daikeler T. Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer. Anti Cancer Drugs. 1999;10:729–733
  135. Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol. 1978;;16:209–216
  136. Grau JJ, Estape J, Alcobendas F, Pera C, Daniels M, Teres J. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomized trial on 134 patients. Eur J Cancer. 1993;29A:340–342
  137. Tsavaris NB, Tentas K, Kosmidis P. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemother. 1996;42:220–226
  138. Grau JJ, Estape J, Fuster J. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol. 1998;16:1036–1039
  139. Cirera L, Balil A, Batiste-Alentorn E. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17:3810–3815
  140. Chun H, Puccio C, Olson C, Ahmed T, Savino J, Mittleman A. Cisplatin plus concurrent continuous infusion (CI) of 5-fluorouracil (5-FU) and paclitaxel: active regimen for adenocarcinoma of the stomach and gastroesophageal junction (GEJ) [abstract 1058]. Proc Am Soc Clin Oncol. 2000;19:271a
  141. Ajani JA, Fodor M, Van Cutsom E. Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (Pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC) [abstract 957]. Proc Am Soc Clin Oricol. 2000;19:247a
  142. Louvet C, Andre T, Tigaud J. Phase II trial of oxaliplatin (OXA) in combination with 5FU and folinic acid (FA) -FOLFOXG regimen- as first line treatment for advanced or metastatic gastric cancer (A/MGC) patients [abstract 1031]. Proc Am Soc Clin Oncol. 2000;19:265a
  143. Engstrom PF, Lavin PT, Klaassen DJ. Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep. 1983;67:713–715
  144. Haffty BG, Son YH, Papac R. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol. 1997;15:268–276
  145. Dobrowsky W, Naude J, Widder J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys. 1998;42:803–806
  146. Kaplan MJ, Hahn SS, Johns ME, Stewart FM, Constable WC, Cantrell RW. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer. Arch Otolaryngol. 1985;111:220–222
  147. Dobrowsky W, Dobrowsky E, Strassl H, Braun O, Scheiber V. Response to preoperative concomitant radio-chemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer. Eur J Cancer Clin Oncol. 1989;5:845–849
  148. Keane TJ, Cummings BJ, O’Sullivan B. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 1993;25:613–618
  149. Abitbol AA, Sridhar KS, Lewin AA. Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C(+/– granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer. 1997;80:266–276
  150. Iop A, Cartei G, Vigevani E, Clocchiatti L, Mansutti M, Sibau AM. Mitomycin C, cisplatin and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas. Am J Clin Oncol. 1997;20:515–518
  151. Andreasson L, Biörklund A, Mercke C. Intra-arterial mitomycin C and intravenous bleomycin as induction chemotherapy in advanced head and neck cancer – a phase II study. Radiother Oncol. 1986;7:37–45
  152. Zakotnik B, Smid L, Budihna M. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: final report. Int J Radiat Oncol Biol Phys. 1998;41:1121–1127
  153. Wheeler RH, Baker SR, Liepman MK, Ensminger WD. Intensive sequential chemotherapy with bleomycin, oncovin, mitomycin C, and methotrexate followed by adriamycin, cisplatin, and cyclophosphamide in squamous cell cancer of the head and neck. Med Ped Oncol. 1983;11:12–19
  154. Dodion P, Cognetti F, van-Rymenant M, Dalesio O, Kirkpatrick A, Rozencweig M. Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell cancer of the head and neck. Eur J Cancer Clin Oncol. 1986;22:241–243
  155. Leyvraz S, Barrelet L, Savary M Bernasconi S. Combination of mitomycin, vindesine, and cisplatin in the treatment of head and neck squamous cell carcinoma. Cancer Treat Rep. 1987;71:81–82
  156. Fountzilas G, Nicolaou A, Sridhar K. Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck. Arch Otorhinolaryngol. 1989;246:373–377
  157. Hashini A, Mahjouhi R, Fandi A. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of the nasopharyngeal type. Ann Oncol. 1999;10:421–425
  158. Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma. Br J Cancer. 1999;80:1962–1967
  159. Isreal L, Chahinian P, Depierre A. Response of 65 measurable epidermoid bronchogenic tumors of known spontaneous doubling time to four different chemotherapeutic regimens – strategic deductions. Med Ped Oncol. 1975;1:83–93
  160. Samson MK, Comis RL, Baker LH, Ginsberg S, Fraile RJ, Crooke ST. Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep. 1978;62:163–165
  161. Veeder MH, Jett JR, Su JQ. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 1992;70:2281–2287
  162. Folman R, Rosman M, Auerbach S. Mitomycin C, vinblastine, and cisplatin (MVP) in the combined modality treatment of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1984;3:
  163. Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RM. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V – a randomized comparison of four cisplatin-containing regimens. J Clin Oncol. 1985;3:72–79
  164. Niell HB, Griffin JP. Combination chemotherapy with mitomycin C, cisplatin, and vinblastine in the treatment of non-small cell lung cancer. Med Ped Oncol. 1985;13:341–345
  165. Ruckdeschel JC, Finkelstein DM, Ettinger DS. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol. 1986;4:14–22
  166. Haedicke K, Camp B, Farber L. Treatment of advanced non-small cell lung cancer (NSCLC) with mitomycin, velban and cisplatin (MVP) at Yale [abstract 716]. Proc Am Soc Clin Oncol. 1986;5:183
  167. Giaccone G, Bagatella M, Donadio M. Mitomycin C, vinblastine and cisplatin. An active regimen for advanced non-small cell lung cancer. Br J Cancer. 1987;56:475–478
  168. Spain RC. Neo-adjuvant mitomycin-C, cisplatin, and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long-term follow-up. Sem Oncol. 1988;16:6–15
  169. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989;60:764–766
  170. Gralla RJ, Kris MG, Potanovich LM, Marks LA, Heelan RT. Enhancing the safety and efficacy of the MVP regimen (mitomycin+vinblastine+cisplatin) in 100 patients with inoperable non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1989;8:
  171. Bonomi PD, Finkelstein DM, Ruckdeschel JC. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Co-operative Oncology Group. J Clin Oncol. 1989;7:1602–1613
  172. Lee SM. Prelininary experience with mitomycin, vinblastine and cisplatin (MVP) combination chemotherapy in the treatment of non-small cell lung cancer at University Hospital, Kuala Lumpur. Singapore Med J. 1990;31:228–232
  173. Mylonakis N, Tsavaris N, Bacoyiannis C. A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol. 1992;3:127–130
  174. Vinante O, Bari M, Segati R. The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer. Oncol. 1993;40:1–4
  175. Wagner H, Lad T, Piantadosi S, Ruckdeschel JC. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIA and IIIB non-small cell cancer of the lung. Chest. 1994;106:348S–354S
  176. Tummarello D, Graziano F, Isidori P, Cellerino R. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients with cisplatin, vinblastine and mitomycin C. Cancer Chemother Pharmacol. 1995;35:249–253
  177. Ellis PA, Smith IE, Hardy JR. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995;71:366–370
  178. Ng KK, Kris MG, Ginsberg RJ. Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III non-small-cell lung carcinoma. Cancer. 1999;86:1189–1197
  179. Klastersky J, Scullier JP, Mommen P. Combination chemotherapy with mitomycin C and vindesine in the treatment of non-small cell lung carcinoma (NSCLC) [abstract 606]. Proc Am Assoc Cancer Res. 1985;26153 (abs 606):
  180. Main J, Hutcheon A. Vindesine and mitomycin C in inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol. 1986;22:983–985
  181. Kris MG, Gralla RJ, Kelson DP. Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment. Chest. 1985;87:368–372
  182. Gridelli C, Airoma G, Incoronato P. Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 1992;30:212–214
  183. Kris MG, Gralla RJ, Wertheim MS. Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep. 1986;70:1091–1096
  184. Miller TP, Vance RB, Ahmann FR, Rodney SR. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a south-west Oncology Group study. Cancer Treat Rep. 1986;70:1101–1104
  185. Einhorm LH, Loehrer PJ, Williams SD. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin-C in advanced non-small cell lung cancer. J Clin Oncol. 1986;4:1037–1043
  186. Rosell R, Abad-Esteve A, Moreno I. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer. 1990;65:1692–1699
  187. Joss RA, Bürki K, Dalquan P. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Cancer. 1990;65:2426–2434
  188. Fukuoka M, Masuda N, Furuse K. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin alternating with vindesine and mitomycin. J Clin Oncol. 1991;9:606–613
  189. Shinkai T, Eguchi K, Sasaki Y. A randomized clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer. 1991;27:571–575
  190. Riggi M, Ruffie P, Voisen S. Influence of pretreatment clinical characteristics on the response rate to mitomycin/ vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. Eur J Cancer. 1991;27:1238–1242
  191. Stockler M, Raghavan D, McCaughan BC. Combination chemotherapy with cisplatin, vindesine and mitomycin C for advanced, inoperable non-small cell lung cancer. Med J Australia. 1992;156:698–700
  192. Fukuoka M, Negoro S, Masuda N. Mitomycin C, vindesine, and cisplatin in advanced non-small cell lung cancer. A phase II study. Am J Clin Oncol. 1992;15:18–22
  193. Burkes RL, Ginsberg RJ, Sheperd FA. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol. 1992;10:580–586
  194. Kleisbauer JP, Thomas P, Perol M. Combination of cisplatin-mitomycin-vindesine for inoperable, non-small cell bronchial cancers. French study group in pneumo-cancerology. Rev Mal Respir. 1993;10:307–312
  195. Gonzalez-Baron M, Felui J, Espinosa E. Comparison of two chemotherapeutic regimens-mitomycin + vindesine + cisplatin (MVP) vs mitomycin + ifosfamide + cisplatin (MIP)-in advanced non-small cell lung cancer. ONCOPAZ Co- operative Group. Ann Oncol. 1994;5:323–327
  196. Perol M, Guerin JC, Thomas P. Multicentre randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. ‘Groupe Francais de Pneumo-Cancerolgie’. Lung Cancer. 1996;14:119–134
  197. Gridelli C, Perrone F, Palmeri S. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin in stage IV non-small-cell lung cancer: A phase III multicentre randomized trial. The ‘Grouppo Oncologico Centro-Sud-Isole’ (G.O.C.S.I.). Ann Oncol. 1996;7:821–826
  198. Ginopoulos P, Spyropoulos K, Kardamakis D. Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE). Cancer Let. 1997;119:241–247
  199. Boni C, Savoldi L, Bisagni G. Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Eur J Cancer. 1998;34:1974–1976
  200. Hejna M, Kornek GV, Raderer M. Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony- stimulating factor for treatment of advanced non-small cell lung carcinoma. Oncol. 1998;55:538–542
  201. Furuse K, Kawahara M, Nishiwaki Y. Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small cell lung cancer. J Clin Oncol. 1999;17:3195–3200
  202. Currie DC, Miles DW, Drake JS. Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer. Cancer Chemother Pharmacol. 1990;25:380–391
  203. Cumin I, Lacroix H, Mahe M, Dutin JP, Dabouis G. Efficacy of the combination of mitomycin. ifosfamide and cisplatin with irradiation for the treatment of cerebral metastases in non-small cell lung carcinoma. Bull Cancer. 1995;82:57–62
  204. Crino L, Corgna E, Porrozzi S. A better therapeutic profile for the combination of mitomycin C, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer: a useful dose-schedule modification. Ann Oncol. 1997;8:709–711
  205. Cullen MH, Billingham LJ, Woodroffe AD. Mitomycin, ifosfamide, and cisplatin in unresectable non-small- cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  206. Ardizzoni A, Addamo GF, Baldini E. Mitomycin- ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatin-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomized phase II study, Italian Lung Cancer Task Force. Br J Cancer. 1995;71:115–119
  207. Gralla RJ, Rittenberg CN, Silverman CR, Marques CB, Maulick JF, Cole JT. Gemcitabine (G) + vinorelbine (V) in combination with mitomycin (N) in non-small cell lung cancer (NSCLC): results of a phase I and phase II study of an active outpatient regimen. Proc Am Soc Clin Oncol. 1998;17:
  208. Sweeney CJ, Sandler AB. Chemotherapy of non-small cell lung cancer. Invest New Drugs. 2000;18:157–186
  209. Wiggens RG, Wolley PV, Macdonald JS, Smythe T, Ueno W, Schein PS. Phase II trial of streptozotocin mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer. 1978;41:387–391
  210. Bukowski RM, Abderhalden RT, Hewlett JS, Weick JK. Groppe CW Jr Phase II trial of streptozotocin mitomycin C and 5-fluorouracil (SMF) in adenocarcinoma of the pancreas. Cancer Clin Trials. 1980;3:321–324
  211. Bitran JD, Desser RK, Kozloff MF, Billings AA. Shapiro CM Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil adriamycin and mitomycin C. (F. A. M). Cancer Treat Rep. 1979;63:2049–2051
  212. Bukowski RM, Balcerzak SP, O’Bryan RM, Bonnet JD, Chen TT. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer. 1983;52:1582–1755
  213. Sternberg CN, Magill GB, Sordillo PP, Cheng EW. MIFA III (mitomycin C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. Am J Clin Oncol. 1984;7:529–533
  214. Cullinan SA, Moertel CG, Fleming TR. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. J Am Med Assoc. 1985;;253:2061–2067
  215. Oster MW, Gary R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer. 1986;57:29–33
  216. J Clin Oncol. 1986;4:1794–1798
  217. Vaughn C, Chapman J, Chinn B. Activity of 5-fluorouracil, mitomycin C and methyl CCNU in inoperable adenocarcinoma of pancreas. Am J Clin Oncol. 1989;12:49–52
  218. Cullinan SA, Moertel CG, Wieand HS. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorourcil, doxorubicin, and cisplatin. Cancer. 1990;63:2207–2212
  219. Todd KE, Gloor B, Lane JS, Isacoff WH, Reber HA. Resection of locally advanced pancreatic cancer after down-staging with continuous infusion 5-fluorouracil, mitomycin C, leucovorin, and dipyridamole. J Gastrointest Surg. 1998;2:159–166
  220. Klapdor, R. Seutter, E. Lang-Polckow, E. M. Reichle, H. Hinrichs, A. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers, Anticancer Res, 1999, 19, 2459, 2469
  221. Stehlin JS, Giovanella BP, Natelson RA. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Internat J Oncol. 1999;14:821–831
  222. Rosemurgy A, Harris J, Langleben A, Casper E, Allen R, Rasmussen H. Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol. 1996;15 207 (abs #471).:
  223. Verweij J, Stoter G. Severe side effects of the cytotoxic drug mitomycin C. Netherlands J Med. 1987;30:43–50
  224. Verwey J, de Vries J, Pinedo HM. Mitomycin C-induced renal toxicity, a dose-dependent side-effect?. Eur J Cancer Clin Oncol. 1987;23:195–199
  225. Montes A, Powles TJ, O’Brien ME, Ashley SE, Luckit J, Treleaven J. A toxic interaction of mitomycin C and tamoxifen causing haemalytic uraemic syndrome. Eur J Cancer. 1993;29A:1854–1857
  226. O’Brien MER, Casey S, Treleaven J, Powles TJ. Use of erythropoietin in the management of the haemalytic uraemic syndrome induced by mitomycin C/tamoxifen. Eur J Cancer. 1994;30A:894–895
  227. Chow S, Roscoe J, Cattran DC. Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin. Am J Kidney Dis. 1986;7:407–412
  228. Garibotto G, Acquarone N, Saffloti S, Deferrari G, Villaggio B, Ferrario F. Successful treatment of mitomycin C-associated hemolytic uremic syndrome by plasmapheresis. Nephron. 1989;51:409–412
  229. Gibbs JB. Mechanism-based target indentification and drug discovery in cancer research. Science. 2000;287:1969–1973
  230. Masferrer JL, Leahy KM, Koki At. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306–1311
  231. Hseuh C-T, Chiu C-F, Kelson DP, Schwartz GK. Selective inhibition of cyclooxygenase-2 enhances mitomycin-c-induced apoptosis. Cancer Chemother Pharmacol. 2000;45:389–396

PII: S0305-7372(00)90202-0

doi: 10.1053/ctrv.2000.0202

Cancer Treatment Reviews
Volume 27, Issue 1 , Pages 35-50 , February 2001

Article Tools